Literature DB >> 15380144

Hirsutism and acne in polycystic ovary syndrome.

Johanna S Archer1, R Jeffrey Chang.   

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine abnormality affecting reproductive age women. Population-based studies estimate a prevalence of 5-10% [Obstet Gynecol 101 (2003) 995; Aust N Z J Obstet Gynaecol 41 (2001) 202]. The clinical characteristics of PCOS include hyperandrogenism, chronic anovulation, insulin resistance and infertility. Hyperandrogenism is generally manifested as hirsutism and acne. Both these clinical symptoms are treated with similar drug therapies, including oral contraceptive pills (OCPs), topical medications or antiandrogens such as spironolactone, flutamide and finasteride, as well as topical medications. Recent studies have shown that lower doses of these medications are as efficacious as high doses and have the advantage of decreased cost and an improved side-effect profile. Although hirsutism and acne can be considered cosmetic in nature, they cause significant social embarrassment and emotional distress. Physicians should be sensitive to these issues and approach patients in a caring and sympathetic manner.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15380144     DOI: 10.1016/j.bpobgyn.2004.05.007

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  21 in total

1.  Interventional studies for polycystic ovarian syndrome in children and adolescents.

Authors:  Patricia Myriam Vuguin
Journal:  Ped Health       Date:  2010-02

Review 2.  Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels.

Authors:  Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh
Journal:  Endocr Rev       Date:  2017-06-01       Impact factor: 19.871

3.  The effects of old, new and emerging medicines on metabolic aberrations in PCOS.

Authors:  Alexandra Bargiota; Evanthia Diamanti-Kandarakis
Journal:  Ther Adv Endocrinol Metab       Date:  2012-02       Impact factor: 3.565

4.  Maternal polycystic ovarian syndrome in autism spectrum disorder: a systematic review and meta-analysis.

Authors:  Maria Katsigianni; Vasilios Karageorgiou; Irene Lambrinoudaki; Charalampos Siristatidis
Journal:  Mol Psychiatry       Date:  2019-03-13       Impact factor: 15.992

5.  Out of bounds? A critique of the new policies on hyperandrogenism in elite female athletes.

Authors:  Katrina Karkazis; Rebecca Jordan-Young; Georgiann Davis; Silvia Camporesi
Journal:  Am J Bioeth       Date:  2012       Impact factor: 11.229

6.  Androgen receptor coregulator long noncoding RNA CTBP1-AS is associated with polycystic ovary syndrome in Kashmiri women.

Authors:  Mudasar Nabi; Syed Mudasir Andrabi; Shayaq Ul Abeer Rasool; Sairish Ashraf; Imran Majid; Shajrul Amin
Journal:  Endocrine       Date:  2021-10-05       Impact factor: 3.633

Review 7.  Light therapies for acne.

Authors:  Jelena Barbaric; Rachel Abbott; Pawel Posadzki; Mate Car; Laura H Gunn; Alison M Layton; Azeem Majeed; Josip Car
Journal:  Cochrane Database Syst Rev       Date:  2016-09-27

8.  Pharmaceutical and Pharmacological Evaluation of the Effect of Nano-Formulated Spironolactone and Progesterone on Inflammation and Hormonal Levels for Managing Hirsutism Experimentally Induced in Rats.

Authors:  Reham I Amer; Ghada E Yassin; Reem A Mohamed; Ahmed M Fayez
Journal:  AAPS PharmSciTech       Date:  2021-07-13       Impact factor: 3.246

9.  Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS.

Authors:  Melanie Landay; Andy Huang; Ricardo Azziz
Journal:  Fertil Steril       Date:  2008-08-22       Impact factor: 7.329

10.  Effect of hCG priming on embryonic development of immature oocytes collected from unstimulated women with polycystic ovarian syndrome.

Authors:  Xiaoying Zheng; Lina Wang; Xiumei Zhen; Ying Lian; Ping Liu; Jie Qiao
Journal:  Reprod Biol Endocrinol       Date:  2012-05-24       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.